Glioblastoma (GBM) is the most common malignant adult primary brain tumor. Despite its high lethality, a small proportion of patients have a relatively long overall survival (OS). Here we report a study of a series of 74 GBM samples from 29 long-term survivors ([LTS] OS !36 months) and 45 non-LTS. Using nextgeneration sequencing, we analyzed genetic alterations in the genes most frequently altered in gliomas. Approximately 20% of LTS had a mutation in the IDH1 or IDH2 (IDH) genes, denoting the relevance of this molecular prognostic factor. A new molecular group of GBMs harbored alterations in ATRX or DAXX genes in the absence of driver IDH or H3F3A mutations. These patients tended to have a slightly better prognosis, to be younger at diagnosis, and to present frontal or temporal tumors, and, morphologically, to present giant tumor cells. A significant fraction of LTS GBM patients had tumors with 1 or more alterations in the relevant GBM signaling pathways (RTK/PI3K, TP53 and RB1). In these patients, the PDGFRA alteration is suggested to be a favorable molecular factor. Our findings here are relevant for developing future targeted therapies and for identifying molecular prognostic factors in GBM patients.
INTRODUCTION
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults and, despite improvements in therapeutic options, it remains one of the deadliest cancers. Even with aggressive surgical resection, radiotherapy and chemotherapy, the median survival is only approximately 16 months from the time of diagnosis. Nevertheless, despite the poor prognosis, 2%-8% of the patients survive for >2 years, and a smaller fraction still survive beyond 3 or even 5 years (1, 2) . These patients are arbitrarily referred to as longterm survivors (LTS).
The recent 2016 review of the CNS WHO classification criteria includes "integrated" histological and relevant molecular parameters that have a strong impact on the diagnosis and classification of gliomas, as well as on their prognosis (3). Mutations of IDH1 or IDH2 (IDH) genes are associated with a more favorable outcome in GBMs, being more common in younger patients and in those with secondary GBM (4, 5) .
The molecular genomic and transcriptomic landscapes of GBMs and lower-grade gliomas have recently been reported (6) (7) (8) (9) , but little attempt has been made to identify the clinical and molecular parameters underlying LTS in GBM, even though this could be crucial for individual therapies. Our aim was to apply next-generation sequencing (NGS) approaches to detect targeted mutations and copy number variation (CNV) in LTS and non-LTS of GBM in order to identify the molecular characteristics underpinning long-term survival.
MATERIALS AND METHODS

Patients and Tissue Samples
Twenty-nine patients with an overall survival (OS) longer than 36 months (LTS > 36) diagnosed with GBM between 2000 and 2015 according to the 2007 WHO classification of tumors of the CNS (3) were retrospectively selected for this study. An additional set of 45 GBM patients consecutively diagnosed between 2014 and 2015 with OS of <36 months (non-LTS < 36) were selected for comparison. Living patients who did not reach the cut-off of 36 months (11 patients) , and patients with an OS <4 months who died due to postsurgery complications or causes not related to tumor aggressiveness (5 patients) were excluded from the comparison analyses between LTS and non-LTS groups, leaving only 29 non-LTS patients suitable for consideration. The 36-month cut-off value was chosen because (1) it represents extremely long-term survival in GBM; (2) the median and mean of survival of the LTS cohort (61.7 and 69.7 months, respectively) is >3 standard deviations above the mean survival of the non-LTS group; and (3) several other authors have also employed this cut-off, allowing comparison of our results with their studies (10) (11) (12) (13) . Patients' clinical data were obtained through a review of their charts.
Hematoxylin and eosin-stained tissue sections were reviewed to verify tumor content (>30% of tumoral cells) and the GBM histopathological diagnosis, which, in accordance with the 2016 WHO classification, were reclassified as: 7 GBM, IDH-mutant, and 67 GBM, IDH-wt cases. Samples were collected at the Virgen de la Salud (Toledo), Ciudad Real University (Ciudad Real) and 12 de Octubre (Madrid) Hospitals. The investigation was approved by the corresponding institutional review boards.
Next-Generation Sequencing
We constructed a next-generation sequencing (NGS) panel comprising 30 genes that had been previously found to be involved in gliomas (Supplementary Data Table S1 ) using Ion AmpliSeq Designer software (Thermo Fisher Scientific, Carlsbad, CA). The design allowed us to analyze the coding sequence (exon padding of 6 5 bp) by the targeted resequencing of 1139 amplicons (average size of 125-175 bp; global panel size of 120.54 kb/sample). The coverage of the submitted loci was 94.55%.
DNA from formalin-fixed, paraffin-embedded (FFPE) tumor tissues was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Manchester, UK). DNA was quantified using a Qubit 2.0 Fluorometer (Thermo Fisher). Library construction and quantification were performed with the Ion AmpliSeq Library Kit v2.0 and the Ion Library Quantitation Kit (Thermo Fisher), respectively. Libraries were multiplexed, submitted to emulsion PCR and sequenced at an average target panel coverage of 800X using the Ion OneTouch 2 system with the Ion PGM Template OT2 200 Kit (Thermo Fisher), following the manufacturer's instructions. For validation purposes, 26 samples were resequenced using additional NGS technology, as previously reported (14) , or the same Ion Torrent technology.
Computational Analysis of NGS Data
The Torrent Mapping Alignment Program (Torrent Suite v.4.2, Thermo Fisher) was used to analyze sequence alignment, variant calling and the variants themselves. Reads were aligned against the hg19 reference genome with the Torrent Mapping Alignment Program (TMAP). After alignment, variants were filtered to exclude variants with: (1) fewer than 30 reads; (2) an allele frequency of <10%; (3) a location outside the exonic or splice regions; (4) synonymous variants; and (5) variants present in the population with a minor allele frequency greater than 1% according to the 1,000 Genomes project (dbSNP build id 138). All the remaining variants were visualized using the Integrative Genomic Viewer (IGV, Broad Institute, http://www.broadinstitute.org/igv/) and were manually reviewed and selected to exclude systematic sequencing errors (15) .
Ion reporter software (Thermo Fisher) was used to detect CNVs. The algorithm uses normalized read coverage across amplicons to predict the copy number or ploidy states. Sample read coverage is compared to a baseline coverage constructed from 10 male control diploid DNA samples. CNV data were filtered to exclude regions with confidences lower than 20 and low precision (<10), as recommended by the manufacturer. Only the following alterations were considered for CNVs: EGFR and PDGFRA amplifications, deletions of PTEN, CDKN2A, RB1 and NF1.
Sanger Sequencing and Pyrosequencing
Hotspot mutations of IDH1, IDH2, H3F3A, and BRAF genes were analyzed by direct Sanger sequencing in an ABI PRISM 310 DNA Analyzer (Applied Biosystems, Foster City, CA), as described elsewhere (16, 17) , or by pyrosequencing assays (18) 
Immunohistochemistry
To detect the IDH1 R132H mutation, a mouse monoclonal antibody (dilution 1: 100, DIA H09, CKPIIIGHHAYGD; Dianova GmbH, Hamburg, Germany) was used. ATRX immunohistochemistry of a polyclonal rabbit antibody (dilution 1: 100, HPA001906; Sigma-Aldrich, St. Louis, MO) was performed using an automated immunostainer (Benchmark Ultra, Ventana, Tucson, AZ) with standard protocols.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) analysis was performed to detect EGFR amplification on paraffinembedded tissue sections using the EGFR/CEN-7 FISH Probe Mix (DAKO Cytomation, Glostrup, Denmark) in 32 of the samples, as reported elsewhere (19) .
MGMT Methylation-Specific PCR
For O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation analysis, DNA was bisulfite-treated using the EZ DNA methylation Kit (Zymo Research, Orange, CA), following the manufacturer's instructions. MGMT promoter methylation status was evaluated by methylationspecific PCR (20) .
Data Validation Using External Data
To validate the results, we searched for data on GBMs with clinical and genomic (mutation and CNV) in The Cancer Genome Atlas (TCGA) database (http://www.cbioportal.org/) and extracted the CNV and mutation data from the same 30 genes included in our NGS assay.
Statistical Analyses
The 2 groups were compared by 2-sided t tests and Fisher exact tests, using RStudio Team (http://www.rstudio. com) and GraphPad Statistics (http//www.graphpad.com). Kaplan-Meier survival curves and log-rank tests, undertaken in SPSS v20.0 (IBM SPSS, Armonk, NY), were used to estimate the survival distribution. A multivariate Cox regression model, using forward-stepwise selection, was developed to estimate p values and hazard ratios (HRs). Statistical significance was concluded for values of p < 0.05.
RESULTS
Clinical Features
The median survival times of the LTS > 36 and non-LTS < 36 patients were 62 months (5.1 years, 36.0À205.0) and 21 months (1.7 years, 4.0À34.5), respectively. A large majority of the patients (87%; 61/70, no data were available from 4 patients) were treated with the current standard treatment for newly diagnosed GBM, which consists of surgery and temozolomide (TMZ) postoperative chemoradiotherapy, followed by 6 cycles of adjuvant TMZ. Importantly, the LTS and non-LTS groups were comparable in terms of the treatment received, with 92% of LTS > 36 and 85% of non-LTS treated under the current standard of care. More than 80% of the cases in each group had undergone a complete or at least 95% resection of the tumor. Even when non-LTS < 36 cases had a higher percentage of partial resection or stereotactic biopsy (17.2%) the difference was not statistically significant (p ¼ 0.19). The median age at diagnosis was 51 years (range 22À72) and 58 years (range 28À78) in LTS > 36 and non-LTS < 36, respectively. Remarkably, 4 of the patients were younger than 30 years. There were no significant differences between groups with respect to the location of the tumor or the symptoms at diagnosis except for headache, which was significantly more frequent in the non-LTS < 36 (31%) than in the LTS > 36 group (7%) (p ¼ 0.04). Detailed information is provided in Supplementary Data Table S2 .
Mutations and Copy Number Variation
The sequence and CNV analyses of the 30 genes analyzed ( Fig. 1) revealed at least 1 nonsilent nucleotide alteration in 84% (62/74) of the patients (an average of 1.8 mutations per patient). Although no sequence mutations were detected in 12 samples, 7 of them presented CNVs (EGFR or PDGFRA amplification, CDKN2A homozygous deletion). Therefore, only 7% of the cases (5/74) showed no mutation or CNV in any of the glioma-related genes analyzed by this NGS panel.
Taking into account the previous reports that revealed 3 main canonical regulatory pathways that are affected in most GBM patients (RTK/PI3K, TP53, and RB1) (7) and other driver or relevant glioma genes (IDH, H3F3A, BRAF, ATRX), we attempted to classify the samples in our series ( Fig. 1): 1) although on a clinical basis only 3 cases were secondary GBMs, 7 patients had mutations of IDH, 5 of whom presented concurrently with ATRX alteration and TP53 mutation; 2) 3 young patients presented mutations of the H3F3A gene, either the K27M (2 cases) or the G34R (1 case) mutation; 3) another case initially diagnosed as a gliosarcoma (2007 WHO) had the V600E mutation of the BRAF gene. When reevaluated, this case was diagnosed as anaplastic pleomorphic xanthoastrocytoma, and was excluded from further analyses; 4) unexpectedly, 6 cases showed an ATRX (4 cases) or DAXX mutation (2 cases) that was concurrent with TP53 mutation but not with any other mutated driver gene (IDH or H3F3A); 5) in 13 cases, we were unable to detect any mutation and/or CNV in the RTK/PI3K pathway or in the IDH, H3F3A or ATRX genes, so we called this group the "no typical mutation" group; 6) considering the genes involved in the RTK/PI3K pathway, 44 patients presented gene alterations: 23 patients in EGFR, 17 in PTEN, 9 in PDGFRA, 6 in the genes coding for the PI3K subunits, 4 in NF1, and 1 in BRAF (not the V600E mutation) (Fig. 1) .
To validate the NGS results, we performed genespecific assays for IDH, BRAF, and H3F3A genes. We also repeated the NGS tests in 26 samples (35% of the series) by using additional NGS technology (14) or by resequencing (Supplementary Data Table S2 ). All of the results were confirmed, indicating a strong consistency of the NGS data.
MGMT Promoter Methylation and TERTp Mutation
Forty-six of the 70 (65%) GBM cases that could be analyzed harbored mutations in TERTp, and the data showed the mutual exclusivity of ATRX and TERTp alterations (Fig. 1) . In addition, most of the cases with alterations in the RTK/PI3K pathway harbored TERTp mutations (84%, 37/44). TERTp mutations were identified in 6 of the 12 tumors that were classified as belonging to the "no typical mutation" group.
All except one of the IDH mutated tumors had undergone MGMT promoter methylation. In the PI3K subgroup, frequencies of methylation were lower, and only 44% of these cases (17/39) exhibited methylation at the MGMT promoter. gene mutation ratio per patient (2.2 and 1.5, respectively) or the frequencies of pathway alterations, except for those cases carrying IDH mutations that were more frequent in LTS (20%) than in non-LTS (0%) (p ¼ 0.06), and for those cases included in the "no typical mutation" group (7% vs 35% in LTS and non-LTS, respectively; p ¼ 0.02) (Table) . Kaplan-Meier curves indicated no significant differences in survival among all pathway groups, although the IDH group had statistically significant better OS than the other groups (p ¼ 0.047), and a tendency towards worse OS was observed for the "no typical" mutation group when compared to the other groups (Supplementary Data Fig. S1 ; p ¼ 0.12). MGMT promoter methylation status was not associated with survival time independently of IDH (p ¼ 0.35). Multivariate Cox regression including variants that may have a significant influence on survival when they are independently considered (age, Karnofsky, IDH and MGMT) revealed that the IDH mutation Regarding the clinical characteristics of the patients with respect to their molecular or pathway alterations, all of the patients who presented IDH mutations were LTS, with a median OS of 72 months (range 48À205). Three of the 5 IDHmutated LTS who lived for 36 months went on to survive for >5 years. The median age at diagnosis was 42 years (range 31À70) and about half of these IDH-mutated patients presented frontal tumor location (3/7) and seizures (4/7). Three patients with H3F3A gene mutations were among the youngest in our sample (median age 32 years): 2 K27M mutated with short OS, and 1 G34R mutated with OS of 56 months.
An intriguing group of patients featured tumors with mutations in the genes coding for the components of the ATRX/DAXX complex and in TP53 but had no additional mutations in the IDH or H3F3A genes (median OS of 30 months, range 14À108; median age at diagnosis of 45 years, range 28À58). Interestingly, one of the DAXX-mutated tumors was diagnosed as a giant cell GBM, a variant of IDH-wildtype GBM. This morphological variant may not have been reported in the patient's histopathological report, so an independent histological review of the 6 cases with ATRX or DAXX mutations was undertaken (by authors JFG, MM, and AH-L). This revealed the presence of giant cells in >20% of the tumoral cells in all of these cases (Fig. 2) . A review of the TCGA cases identified 8 cases with DAXX (3 cases) or ATRX (5 cases) mutations in the absence of IDH or H3F3A mutations. We personally reviewed the available images (http://www.cbioportal.org) and at least 3 of these cases showed giant cells (cases TCGA-06-0238-01, TCGA-06-0213-01, and TCGA-06-5858-01).
Considering the RTK/PI3K pathway, although we found no significant differences in the frequency of PDGFRA alterations between the survival groups, or between the KaplanMeier survival curves, the median OS was longer in PDGFRA-altered tumors (40 months, 23À58). None of the clinical or molecular variables analyzed in this study (including CNVs, mutations and MGMT methylation) was able to explain the difference in survival within this PI3K group. Thirteen patients were from the LTS > 36 group (median OS of 62 months), while the other 13 patients belonged to the non-LTS < 36 group (median OS of 21 months). It should be noted that the PI3K pathway, a commonly altered pathway in IDHwild type GBMs, was found to be altered in those patients who showed extra-long survival (7 of the 13 LTS > 36 patients lived for >5 years).
Finally, we were unable to detect mutations in any of the genes covered by this panel in 13 of the samples (except for a TP53 mutation in 1 case). Most of these cases (10/13) belonged to the non-LTS < 36 group, and 7 of them survived for <10 months (median OS of 8 months) (Table; Fig. 1 ). In this "no typical mutation" group, TERTp mutation was present in 6 of 13 cases. The median age of this group at diagnosis was 63 years, although the difference compared with patients with the PI3K-altered pathway or the remainder of the series was not statistically significant (p ¼ 0.53).
Analysis of TCGA Data
Clinical and genomic data were available from 273 patients included in the TCGA database, of whom 170 fitted the selection criteria used in this study: 18 tumors belonged to the LTS > 36 and 152 to the non-LTS groups. The clinical characteristics of the TCGA series are summarized in the Supplementary Information. In the TCGA series we were able to identify all of the groups highlighted in this study, except for the H3F3A one. Similar frequencies of pathway alteration to that identified in our series were observed in the TCGA series. Furthermore, the Kaplan-Meier curves showed longer survival for the IDH group of the TCGA series (p ¼ 0.001), and the TCGA "nonmutations" group had the shortest median OS. No other differences between survival groups using the TCGA data were identified (Supplementary Information). Comparisons between LTS > 36 and non-LTS < 36 groups in our series. 
DISCUSSION
Three studies have identified various clinical features related to longer survival, including age, Karnofsky performance status, extent of surgical resection, tumor location and postoperative chemoradiotherapy treatments (11, 21, 22) . In addition, well-known molecular biomarkers have been associated with this long-term survival of GBM patients; MGMT promoter methylation (predicts a better response to chemotherapy) and IDH mutations (related to a better prognosis). Nevertheless, additional factors explaining this LTS should be present, as a notable proportion of long-term survivors show neither MGMT promoter methylation nor IDH mutation (12, 13) .
We used gene-targeted NGS to exhaustively analyze the somatic DNA mutations and CNV alterations that occur in the genes most frequently altered in gliomas in order to identify biomarkers associated with the LTS of GBM patients. The most striking difference observed between LTS and non-LTS was associated with the IDH mutation, consistent with previous studies reporting IDH mutations in approximately 30% of cases of LTS (12, 13) . Therefore, our results and those of other authors support the role of IDH as an important molecular factor determining the LTS of GBMs, although a significant fraction of LTS patients do not carry this mutation.
Previous comprehensive genome-, transcriptome-, and proteome-wide analyses have demonstrated the importance of the 3 signaling pathways most frequently altered in GBM, the RTK/PI3K, TP53, and RB pathways, which affect more that 70% of primary GBMs (7, 23) . Our study found no differences in the genomic alterations affecting these pathways between LTS patients and those who live <36 months following diagnosis and shows that the RTK/PI3K was the main affected pathway even in LTS GBM patients. Nevertheless, a higher frequency of PDGFRA alterations occurring in LTS compared with non-LTS (14% vs 7%) was observed. Indeed, a frequent PDGFRA chromosomal gain in IDH wild-type GBM patients with long-term survival compared with IDH-wild type non-LTS GBMs has also been suggested in 2 recent publications, consistent with our findings (13, 24) . Taking together the results of our study, those of these 2 previous studies, and the data in the TCGA database, these differences are significant (p ¼ 0.04). Therefore, although additional studies with a larger LTS sample are required, these data suggest that the PDGFRA alteration in GBM patients could be of prognostic value.
No other molecular differences were identified in our series between the PI3K-altered (IDH wild-type) LTS and non-LTS GBM patients, in contrast to the results of other studies showing a lower rate of EGFR amplification in LTS GBM patients (12, 25) . Other, unknown factors not studied here most likely explain the differences between the 2 PI3K-affected survival groups.
A striking finding of the present study is the identification of a group of GBMs with a slightly better prognosis that exhibit alteration of ATRX or DAXX, because they occurred in the absence of IDH or H3F3A mutations. The existence of this GBM molecular subgroup has also been proposed recently, consistent with our results (26) . The histopathological review revealed the presence of giant cells in all these cases, as was confirmed in the TCGA series. A recent study also showed a higher frequency of ATRX loss of expression by immunohistochemistry in giant cell GBM (19%) in the absence of IDH mutation (5%), although other chromatin remodeling genes, such as DAXX, were not analyzed in this study (27) . Here we suggest that giant cell GBMs may have quite specific molecular characteristics, such as the presence of ATRX/DAXX in the absence of IDH or H3F3A driver mutations. These findings are consistent with those reported in young GBM patients, suggesting that specific histological patterns feature different molecular GBM subgroups (28) . Furthermore, clinical characteristics such as young age at diagnosis and frontal and temporal tumor location (in 5 out of 6 ATRX/DAXX-mutated patients) are largely confined to this ATRX/DAXX GBM group. No other remarkable histological feature (epithelioid morphology, gliosarcoma component, gemystocytes, PNETlike foci, small cells, or oligo-like component) was identified particularly associated to a molecular or survival group (Supplementary Data Table S2 ).
Another remarkable finding of our report is the tendency towards worse OS in the absence of typical gene mutations identified within a group of 13 patients, of whom more than half survived for <8 months following diagnosis. Further work is needed to explore the genetic alterations in these patients.
Our study is limited in 4 notable ways. First, although this is one of the largest series of LTS analyzed so far, the sample size is still too small for group differences of the magnitude observed to be statistically significant, for which reason we used data from other databases and reports to validate the results. Second, the gene-targeted panel used for this study analyzes only the 30 genes that are most frequently mutated in gliomas. The possibility of other alterations being present at the genomic, transcriptomic or protein levels that may be relevant to patient survival, were not considered. Third, the fact that this is a retrospective study in which a small fraction of the patient population was not treated under the current standard of care, and in which second-line treatments varied from patient to patient, may have introduced a degree of variability into the results obtained. Finally, the fact that the 2 groups of samples (LTS and non-LTS) were collected at different times may have produced differential success in variant detection, as formalin fixation of FFPE samples can cause serious difficulties with molecular testing, such as DNA fragmentation and nonreproducible sequencing artefacts. We tried to minimize this limitation by employing strict filtering criteria and by validating the NGS results.
In conclusion, the molecular NGS analysis performed here identifies factors associated with the rare long survival time of GBM patients, such as alterations of IDH and PDGFRA. However, it also indicates that additional, unknown factors contribute to the extra-long survival found in IDH-wild type GBMs, since these patients are molecularly indistinguishable from those non-LTS GBMs with alterations in the 3 main GBM-affected pathways.
